Galectin Therapeutics Inc

GALTNASDAQ · USD
2.91USD-0.07 (-2.52%)
115

Galectin Therapeutics Inc (GALT) Covered Calls

Galectin Therapeutics Inc trades in the Biotechnology industry with an IV Rank of 15.08%, low versus the past year. GALT's highest covered call setup is the $10.00 strike expiring Jan 15, 2027, sorted by theoretical annualized return. It's 243.64% out of the money with 59 days to expiration, a 245.36% return until expiration, and a 1,517.91% theoretical annualized return. Across the setups shown, annualized returns run from 62.42% to 1,517.91% at strikes between $5.00 and $10.00, with 59 to 430 days to expiration, as of Nov 17, 2026.

Read more

Running GALT covered calls helps you generate income from Galectin Therapeutics Inc shares you already own, turning a long stock position into a yield producing asset. A covered call means holding the underlying stock and selling a call option against it, collecting premium in exchange for capping upside at the strike. Use our scanner to find the best GALT covered calls in real time and filter for the strikes, expiries, and premiums that fit your strategy.

A covered call pairs limited risk with a clear income profile. If GALT stays below the strike at expiration, you keep the premium and the shares. If it rises above, you deliver the stock at the strike and still pocket the premium. Selling GALT covered calls works best when implied volatility is elevated, since richer premiums improve the risk reward. Key inputs include strike selection relative to delta, days to expiration, annualized return, and probability of assignment, all of which determine whether a given GALT covered call is worth writing.

Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. The company's lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, a galactoarabino-rhamnogalacturonan polysaccharide polymer that is in Phase III clinical trial for the treatment of liver fibrosis associated with fatty liver disease and non-alcoholic steatohepatitis cirrhosis, as well as for the treatment of cancer. It also engages in developing GM-CT-01, which is in pre-clinical development stage for the treatment of cardiac and vascular fibrosis, as well as focuses on developing belapectin for the treatment of psoriasis, and lung and kidney fibrosis.

2027-01-155910.00243.640.050.35714.00245.361517.91-1.72+0.191,1160.30
2027-01-15597.50157.730.050.15464.00159.45986.43-1.72+0.139500.10
2027-01-15595.0071.820.100.30219.0075.26465.58-3.44+0.261,3310.20
2027-04-161505.0071.820.050.80214.0073.54178.95-1.72+0.392170.75
2028-01-214305.0071.820.052.85214.0073.5462.42-1.72+0.713292.80

As of Nov 17, 2026

Prices move. This one stays.Lock in 5 years at a special price and save $1,503. Ending soon.See the Black Friday deal →

Stock Statistics

  • IndustryBiotechnology
  • SectorHealthcare
  • IV Rank15.08% Low
  • Market cap (M$)301
  • 52 weeks high-58.20%
  • 52 weeks low47.52%
  • Analyst recommendationStrong Buy
    1.00
  • Target price$11.00
    278.66% above the current stock price
  • Dividend—
  • Payout ratio—
  • Earnings date2026-11-16
  • P/E—
  • Future P/E—
  • EPS (ttm)-0.34
  • EPS growth next 5 years—

As of Nov 18, 2026